Why the study?
Does the addition of corticosteroids or infliximab to IVIg reduce progression in CAA size in high-risk patients with Kawasaki disease and baseline CAA?
Does the addition of corticosteroids or infliximab to IVIg reduce progression in CAA size in high-risk patients with Kawasaki disease and baseline CAA?
Adjunctive therapy with corticosteroids or infliximab added to IVIg may reduce the progression of coronary artery aneurysms in high-risk patients with Kawasaki disease.
Answers are grounded in this paper and cite their sources.
May support adjunctive therapy in high-risk Kawasaki disease with CAA; leaves open need for randomized confirmation before practice change.
Among a high-risk group of patients with Kawasaki disease with CAA on baseline echocardiography, those treated with corticosteroids or infliximab in addition to IVIg had less progression in CAA size compared with those treated with IVIg alone. Prospective randomized trials are needed to determine the best adjunctive treatment of patients who present with CAA.
No takes yet. Share an insight, caveat, or question.
Dionne et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: